# A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS

> **NCT03593915** · PHASE1,PHASE2 · TERMINATED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 20 (actual)

## Conditions studied

- Myelodysplastic Syndromes (MDS)

## Interventions

- **COMBINATION_PRODUCT:** Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine

## Key facts

- **NCT ID:** NCT03593915
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-29
- **Primary completion:** 2021-08-16
- **Final completion:** 2021-08-16
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** The sponsor decided not to continue the study based on the overall company strategy in AML.
- **Last updated:** 2023-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03593915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03593915, "A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03593915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*